- ￥2200 - 61500
- 齐源
- 127680
- 国产/进口
- 2025年07月14日
- FC, Depletion, IHC
- 大鼠
- 小鼠
7 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
Ly-6G
- 级别：
Ly-6G Antibody
- 目录编号：
Ly-6G Antibody
- 克隆性：
单克隆
- 抗原来源：
大鼠
- 保质期：
Ly-6G Antibody
- 抗体英文名：
Ultra-LEAF™ Purified anti-mouse Ly-6G Antibody
- 抗体名：
Ly-6G Antibody
- 标记物：
Ly-6G Antibody
- 宿主：
大鼠
- 适应物种：
小鼠
- 免疫原：
Ly-6G Antibody
- 亚型：
Ly-6G Antibody
- 形态：
Ly-6G Antibody
- 应用范围：
FC, Depletion, IHC
- 保存条件：
2-8℃
- 浓度：
Ly-6G Antibody
- 规格：
100 µg/1 mg/5 mg/25 mg/50 mg/100 mg
| 规格： | 100 µg | 产品价格： | ￥2200.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥2700.0 |
| 规格： | 5 mg | 产品价格： | ￥9800.0 |
| 规格： | 25 mg | 产品价格： | ￥25600.0 |
| 规格： | 50 mg | 产品价格： | ￥42800.0 |
| 规格： | 100 mg | 产品价格： | ￥61500.0 |
Ultra-LEAF™ Purified anti-mouse Ly-6G Antibody详细如下：
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxinlevel is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
Preparation ：The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration ：The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentrationand expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™solution contains no preservative; handle under aseptic conditions.
Application ：FC - Quality tested、Depletion, IHC - Reported in the literature, not verified in house
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cellsin 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimalperformance for each application.
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxinlevel is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
Preparation ：The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration ：The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentrationand expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™solution contains no preservative; handle under aseptic conditions.
Application ：FC - Quality tested、Depletion, IHC - Reported in the literature, not verified in house
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cellsin 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimalperformance for each application.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Haffner–Luntzer M, et al. 2019. Proc Natl Acad Sci U S A. 116:8615. PubMed
2. Gawish R, et al. 2022. Elife. 11:. PubMed
3. Deng H, et al. 2021. J Immunother Cancer. 9: . PubMed
4. Prystaz K, et al. 2018. Am J Pathol. 188:474. PubMed
5. Mödinger Y, et al. 2018. Am J Pathol. 189:147. PubMed
6. Kaiser R, et al. 2021. JCI Insight. 6:e150862. PubMed
7. Kuhn MR, et al. 2022. Front Endocrinol (Lausanne). 13:997745. PubMed
8. Hu J, et al. 2022. J Immunol Res. 2022:7966089. PubMed
9. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
10. Kim AD, et al. 2021. Sci Rep. 11:24194. PubMed
11. Shang Q, et al. 2020. Cell Death Dis. 0.949305556. PubMed
12. Fischer V, et al. 2022. J Bone Miner Res. 37:137. PubMed
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Haffner–Luntzer M, et al. 2019. Proc Natl Acad Sci U S A. 116:8615. PubMed
2. Gawish R, et al. 2022. Elife. 11:. PubMed
3. Deng H, et al. 2021. J Immunother Cancer. 9: . PubMed
4. Prystaz K, et al. 2018. Am J Pathol. 188:474. PubMed
5. Mödinger Y, et al. 2018. Am J Pathol. 189:147. PubMed
6. Kaiser R, et al. 2021. JCI Insight. 6:e150862. PubMed
7. Kuhn MR, et al. 2022. Front Endocrinol (Lausanne). 13:997745. PubMed
8. Hu J, et al. 2022. J Immunol Res. 2022:7966089. PubMed
9. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
10. Kim AD, et al. 2021. Sci Rep. 11:24194. PubMed
11. Shang Q, et al. 2020. Cell Death Dis. 0.949305556. PubMed
12. Fischer V, et al. 2022. J Bone Miner Res. 37:137. PubMed
相关实验
7211011 小鼠淋巴细胞分离液 达优 100339 Ultra-LEAF™ Purified anti-mouse CD3ε Antibody BioLegend 102115 Ultra-LEAF™ Purified anti-mouse CD28 Antibody BioLegend CD3/CD28 Streptamer® 多聚体法： 货号 名称
总蛋白（包括质膜和细胞器膜蛋白），但费时费力。目前，有一种最新型有效的膜蛋白提取工具，并具有高纯度、高特异性、高载量温和提取的优点。是基于1980年科学家在牛眼视网膜中发现的一种命名为Rho1D4的氨基酸序列以及其对应的抗体来作为亲和标签纯化膜蛋白取得了非常好的效果，将Rho1D4抗体链接在琼脂糖或磁珠上，用于亲和层析带有Rho1D4标签的膜蛋白，能近乎完美的解决这些研究难题。1） 什么是Rho1D4?Rho1D4是指在牛眼视网膜细胞内的牛视紫红质C端的最后九位氨基酸。Rho1D4得名于与该序列
文献支持
Ultra-LEAF™ Purified 抗小鼠 Ly-6G 抗体
￥2200 - 61500
